BMO Capital lowered the firm’s price target on Sarepta (SRPT) to $50 from $70 and keeps a Market Perform rating on the shares. Sarepta management hosted a call to discuss the death of a patient in the limb-girdle muscular dystrophy trial, with questions mainly revolving around the reasons behind management not disclosing the patient death during the July 16 conference call and how management will be disclosing patient deaths moving forward, and the potential readthrough from the LGMD death to SRP-9004/Elevidys approval and uptake, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target lowered to $18 from $32 at Piper Sandler
- Sarepta price target lowered to $20 from $28 at JPMorgan
- Sarepta downgraded to Underperform from Hold at Needham
- Buy Rating for Sarepta Therapeutics Amid Elevidys’ Continued Use in Ambulatory Patients
- Sarepta price target lowered to 0c from $10 at H.C. Wainwright